{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Table 9 - Summary of adverse event reporting instructions', 'Event', 'Reporting', 'Specific events in this category', 'Case Report Form completion', 'category', 'timeframe', 'AE form', 'Safety', 'Other', 'Complementary', 'specific', 'Form', 'forms', 'AE (nonSAE,', 'Routine', 'Any AE that is not an SAE or AESI', 'Yes', 'No', 'No', 'nonAESI)', 'SAE (nonAESI', 'Expedited (within', 'Any AE meeting seriousness criterion per', 'Yes', 'Yes', 'No', 'or AESI)', '24 hours)', 'Section 10.4.1.3', 'AESI', 'Expedited (within', 'Acute hypersensitivity/ anaphylaxis', 'Yes', 'Yes', 'No', '24 hours)', 'Pregnancy', 'Yes', 'Yes', 'Yes', 'Symptomatic overdose', 'Yes', 'Yes', 'No', 'ALT>=3ULN or >= 2 baseline', 'Yes', 'Yes', 'Yes', 'Autoimmune mediated conditions including but not', 'Yes', 'Yes', 'No', 'limited to autoimmune encephalitis, cytopenias, ITP,', 'autoimmune hepatitis, nephropathies including anti-', 'glomerular basement membrane (GBM) disease,', 'thyroid disorders and acquired Hemophilia A', 'Temporally associated* pulmonary alveolar', 'hemorrhage', 'Temporally associated* myocardial ischemia,', 'myocardial infarction', 'Temporally associated* stroke', 'Temporally associated* cervicocephalic arterial', 'dissection', '(* Temporally associated: 1 to 3 days after the last', 'infusion)', 'HLH,', 'Progressive multifocal leukoencephalopathy (PML)', 'Pneumonitis,', 'Serious infections including serious opportunistic', 'infections (eg, Listeria infections, CMV, EBV), HPV', 'associated with cervical dysplasia', 'Malignancy', 'Thrombotic thrombocytopenic purpura', 'Abbreviations: AE: adverse events; AESI: adverse event of special interest; ALT: alanine aminotransferase; IMP: investigational medicinal', 'product; ITP: immune thrombocytopenia; nonSAE: nonserious adverse events.', '10.4.7 Guidelines for reporting product complaints (IMP/NIMP/device)', 'Any defect in the IMP/NIMP/device (alemtuzumab/oral prednisone/prednisolone 1 mg/kg or', '50 mg, and H2 antagonist) must be reported as soon as possible by the Investigator to the', 'monitoring team that will complete a product complaint form within required timelines.', 'Appropriate information (eg, samples, labels or documents like pictures or photocopies) related to', 'product identification and to the potential deficiencies may need to be gathered. The Investigator', 'will assess whether or not the quality issue has to be reported together with an AE or SAE.', 'Property of the Sanofi Group - strictly confidential', 'Page 82', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '10.5 OBLIGATIONS OF THE SPONSOR', 'Adverse events that are considered expected will be specified by the reference safety information', '(label).', 'During the course of the study, the Sponsor will report in an expedited manner:', 'All SAEs that are both unexpected and at least reasonably related to the IMP (SUSAR), to', 'the regulatory authorities, independent ethics committee (IECs)/institutional review boards', '(IRBs) as appropriate and to the Investigators.', 'All SAEs that are expected and at least reasonably related to the IMPs to the regulatory', 'authorities, according to local regulations.', 'The Sponsor will report all safety observations made during the conduct of the trial in the clinical', 'study report.', '10.6 SAFETY INSTRUCTIONS', 'For more information about alemtuzumab, please refer to label.', '10.7 ADVERSE EVENTS MONITORING', 'All events will be managed and reported in compliance with all applicable regulations, and', 'included in the final clinical study report.', 'Property of the Sanofi Group - strictly confidential', 'Page 83', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}